Peregrine Capital Management LLC purchased a new stake in Glaukos Co. (NYSE:GKOS – Get Rating) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 115,452 shares of the medical instruments supplier’s stock, valued at approximately $5,043,000. Peregrine Capital Management LLC owned 0.24% of Glaukos at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quadrant Capital Group LLC raised its stake in shares of Glaukos by 262.4% in the 3rd quarter. Quadrant Capital Group LLC now owns 1,011 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 732 shares during the period. Captrust Financial Advisors raised its stake in shares of Glaukos by 119.5% in the 1st quarter. Captrust Financial Advisors now owns 1,484 shares of the medical instruments supplier’s stock valued at $86,000 after purchasing an additional 808 shares during the period. HighTower Advisors LLC acquired a new stake in shares of Glaukos in the 1st quarter valued at about $208,000. AlphaCrest Capital Management LLC acquired a new stake in shares of Glaukos in the 3rd quarter valued at about $205,000. Finally, Two Sigma Advisers LP acquired a new stake in shares of Glaukos in the 3rd quarter valued at about $207,000. Institutional investors and hedge funds own 92.17% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have issued reports on GKOS. Citigroup lifted their price target on Glaukos from $57.00 to $59.00 and gave the company a “buy” rating in a research note on Thursday, February 23rd. JPMorgan Chase & Co. lifted their target price on Glaukos from $42.00 to $48.00 and gave the company a “neutral” rating in a research report on Thursday, February 23rd. Stephens lowered their target price on Glaukos from $69.00 to $68.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 28th. Needham & Company LLC lowered their target price on Glaukos from $58.00 to $57.00 and set a “buy” rating on the stock in a research report on Thursday, February 23rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Glaukos in a research report on Wednesday, February 22nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $56.67.
Glaukos Stock Performance
Glaukos (NYSE:GKOS – Get Rating) last announced its quarterly earnings results on Wednesday, February 22nd. The medical instruments supplier reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.03. The firm had revenue of $71.23 million for the quarter, compared to the consensus estimate of $67.71 million. Glaukos had a negative return on equity of 18.51% and a negative net margin of 35.07%. Analysts predict that Glaukos Co. will post -2.38 EPS for the current year.
Glaukos Company Profile
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B.
- Get a free copy of the StockNews.com research report on Glaukos (GKOS)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.